Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background and aims Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of drugs that lower glucose by inducing renal glycosuria. We aimed to explore whether SGLT2 inhibitor added to the usual care for patients with type 2 diabetes mellitus (T2DM) and biopsy-proven nonalcoholic steatohepatitis (NASH) will benefit NASH histology. Methods In this investigator-initiated, single-arm, open-label, pilot study, nine biopsy-proven NASH patients with T2DM were given empagliflozin 25 mg daily for 24 weeks. Liver biopsy was repeated at the end of treatment. The histological outcomes were compared with the placebo group of a previous 48-week clinical trial. Results There was a significant reduction in body mass index (median change, Δ = -0.7 kg per m 2 , p = 0.011), waist circumference (Δ = -3 cm, p = 0.033), systolic blood pressure (Δ = -9 mmHg, p = 0.024), diastolic blood pressure (Δ = -6 mmHg, p = 0.033), fasting blood glucose (Δ = -1.7 mmol/L, p = 0.008), total cholesterol (Δ = -0.5 mmol/L, p = 0.011), gamma glutamyl transpeptidase (Δ = -19 U/L, p = 0.013), volumetric liver fat fraction (Δ = -7.8%, p = 0.017), steatosis (Δ = -1, p = 0.014), ballooning (Δ = -1, p = 0.034), and fibrosis (Δ = 0, p = 0.046). All histological components either remained unchanged or improved, except in one patient who had worsening ballooning. Empagliflozin resulted in significantly greater improvements in steatosis (67% vs. 26%, p = 0.025), ballooning (78% vs. 34%, p = 0.024), and fibrosis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the amount of weight loss determined the amount of liver lipid reduction for both empagliflozin [98] and canagliflozin [155] in respective RCTs.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [155]
In the citing paper
“Utilizing imaging methods, canagliflozin failed to induce a statistically significant reduction in liver lipid content [152]”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [152]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cited by
Items 101–192 of 192
Alomari, M., Rashid, M. U., Chadalavada, P. N., Ragheb, J. G., Zafar, H., Suarez, Z. K., Khazaaleh, S., Gonzalez, A. J., & Castro, F. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.477 · Cited by 13
What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas, M. N., Imprialos, K. P., Stavropoulos, K., & Athyros, V. G. (2019) · Current Vascular Pharmacology · doi:10.2174/157016111705190703102816 · Cited by 11
Osman, A. T., Sharkawi, S. M. Z., Hassan, M. I. A., Abo‐Youssef, A. M., & Hemeida, R. A. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119638 · Cited by 12
RetractedMiyake, T., Yoshida, O., Matsuura, B., Furukawa, S., Hirooka, M., Abe, M., Tokumoto, Y., Koizumi, Y., Watanabe, T., Takeshita, E., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01239-7 · Cited by 12
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Yaribeygi, H., Maleki, M., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · EXCLI journal · doi:10.17179/excli2023-6022 · Cited by 13
Hojná, S., Malínská, H., Hüttl, M., Vaňourková, Z., Marková, I., Miklánková, D., Hrdlička, J., Papoušek, F., Neckář, J., Kujal, P., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116520 · Cited by 11
Fujimori, N., Tanaka, N., Kimura, T., Sano, K., Horiuchi, A., Kato, N., Takahashi, Y., Kuribayashi, N., Sugiura, A., Yamazaki, T., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-01018-1 · Cited by 9
Samuel, S., Abulawi, A., & Malik, R. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030018 · Cited by 11
Esmaeili, A., Azar, R. P., Hosseiniazar, M. M., & Gharabagh, L. H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.723 · Cited by 10
Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients
Yen, F., Wei, J. C., Wang, C., Hou, M., Yu, T., Huang, Y., Hwu, C., & Hsu, C.-C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112174 · Cited by 9
Connelly, M. A., Rivera, J. V., Guyton, J. R., Siddiqui, M. S., & Sanyal, A. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15935 · Cited by 11
Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)
Khan, A., Ross, H. M., Parra, N. S., Chen, S. L., Chauhan, K., Wang, M., Yan, B. M., Magagna, J., Beiriger, J., Shah, Y., et al. (2022) · Livers · doi:10.3390/livers2040022 · Cited by 13
Katsuyama, H., Hakoshima, M., Iijima, T., Adachi, H., & Yanai, H. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem632 · Cited by 10
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status
Boccatonda, A., D’Ardes, D., Moronti, V., Santilli, J., Cipollone, A., Lessiani, G., Gregorio, N. D., Serra, C., Piscaglia, F., Ferri, C., et al. (2024) · Medicina · doi:10.3390/medicina60111781 · Cited by 10
Ogawa, Y., Nakahara, T., Ando, Y., Yamaoka, K., Fujii, Y., Uchikawa, S., Fujino, H., Ono, A., Murakami, E., Kawaoka, T., et al. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002588 · Cited by 8
Ao, N., Du, J., Jin, S., Suo, L., & Yang, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16043 · Cited by 9
Procyk, G., Jaworski, J., Gąsecka, A., Filipiak, K. J., & Borovac, J. A. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.09.001 · Cited by 7
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
Salah, H. M., & Fudim, M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.011 · Cited by 6
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
Bañares, J., Manzano-Núñez, R., Prio, A., Rivera‐Esteban, J., Camps-Relats, L., Villarejo, A., Ruiz‐Ortega, L., Pons, M., Ciudin, A., Salcedo, M. T., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.945626 · Cited by 6
Khan, R. S., & Newsome, P. N. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05573-y · Cited by 6
Gameil, M. A., Abdelgawad, M., Bahgat, M., El-Sebaie, A. H., & Marzouk, R. E. (2020) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-020-00013-0 · Cited by 5
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 7
Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis
Schattenberg, J. M. (2020) · Visceral Medicine · doi:10.1159/000507231 · Cited by 5
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Lin, J., Ren, T., Zhao, Q., Tong, Q., Liu, J., Ye, K., & Yuan, Y. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03899-3 · Cited by 6
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Cabrera-Angeles, J. C., Hernández-Alba, A. L., García‐Arroyo, F. E., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Aparicio‐Trejo, O. E., del Valle‐Mondragón, L., Martínez-Olivares, C. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189010 · Cited by 4
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 10
Sodium‐glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside
Bagheri, B., Yaribeygi, H., Taherifard, E., Talasaz, A. H., Bagheri, H., Darban, M., Tabrizi, R., Najafi, S., Khodadost, M., & Akbari, M. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12852 · Cited by 4
Васильевна, Ц. О., Тимощенко, О. В., Tuzovskaia, O. V., Latyntseva, L. D., & Nikolaev, К. Y. (2022) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20220601 · Cited by 4
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Арманович, А. А., Sheibani, M., Трофименко, А. И., Lysov, E. E., Khamidova, F. M., Aznauryan, A., Sukiasyan, L. M., Sahakyan, K., Gevorgyan, T. R., Tatoyan, M. R., et al. (2025) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2025-10-1-101-109 · Cited by 3
Mehr, K. N., Shokry, J., Ahangar, H. G., Pirshahid, M. E., Seyedalipour, S. F., Emami, A., & Meftah, N. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-150453 · Cited by 4
Rao, A. K., Ibrahim, A. B., & Rockey, D. C. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.04.019 · Cited by 3
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
Welches (ist das richtige) Target bei nichtalkoholischer Fettleber (NAFLD)
Huber, Y., Galle, P. R., & Schattenberg, J. M. (2020) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1068-3981 · Cited by 5
Lee, C. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.01.005 · Cited by 3
Ahmed, S. H., Moeed, A., Waqar, E., Rizwan, S., Hasnain, N., Qamar, M. A., Fatima, K., & Minhas, A. M. K. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100437 · Cited by 3
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. II. Kezelés
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
Kostitska, I. O., Protas, N., & Petrovska, L. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-01 · Cited by 3
Liang, L. Y., Wong, V. W., Hui, V. W., Yip, T. C., Tse, Y., Lui, G. C.-Y., Chan, H. L., & Wong, G. L. (2021) · GastroHep · doi:10.1002/ygh2.471 · Cited by 4
Ishimaru, Y., Kessoku, T., Nonaka, M., Kitajima, Y., Hyogo, H., Nakajima, T., Imajo, K., Kubotsu, Y., Isoda, H., Kawanaka, M., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4456-24 · Cited by 2
Choi, J., Fulop, D., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0825 · Cited by 12
Soyaltın, U. E., Şimşir, İ. Y., & Akıncı, B. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02633-w · Cited by 2
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review
Ștefan, A. G., Mitrea, A., Clenciu, D., Vladu, I. M., Roșu, M. M., Timofticiuc, D. C. P., Gheonea, T. C., Efrem, I. C., Amzolini, A. M., Vladu, B. E., et al. (2026) · Medicina · doi:10.3390/medicina62020325 · Cited by 5
Association of insulin resistance and non-alcoholic fatty liver disease
Mishina, E. Е., Mayorov, A. Y., Bogomolov, P., Liusina, E. O., & Bueverov, A. O. (2021) · Diabetes Mellitus · doi:10.14341/dm12234 · Cited by 2
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2025) · Diabetes mellitus · doi:10.14341/dm13340 · Cited by 1
Kemiset, D. (2023) · Journal of Pharmaceutical Negative Results · doi:10.47750/pnr.2022.13.s08.478 · Cited by 1
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 2
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
Aggarwal, P., Singh, T., & Alkhouri, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00533-x · Cited by 1
Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie
Apostolopoulou, M., & Roden, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_20 · Cited by 1
Effect of sodium-glucose cotransporter type 2 inhibitors on non-alcoholic fatty liver disease
Суплотова, Л. А., Kulmametova, D. S., Fedorova, A. I., Сергеевна, Д. Т., & Makarova, O. B. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-15-83-89 · Cited by 2
Metabolic effects of empagliflozine
Кедик, А. В., & Kutsin, O. O. (2022) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2022-5-04 · Cited by 3
El Hígado graso (parte 2): enfoque clínico y tratamiento
Ortíz, J. E. P., Luque, C. B. S., & Quiróz, R. J. O. (2023) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.979 · Cited by 1
Tkach, S. M. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-3-62 · Cited by 1
Diabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Chang, A. J., Bhatt, A. S., & Ambrosy, A. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2960 · Cited by 1
Patoulias, D., & Doumas, M. N. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001591
Empagliflozin senkt effektiv den Leberfettgehalt bei gut kontrolliertem Typ-2-Diabetes
Chakaroun, R. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00599-7
Nsihino, K., Ishii, K., Tanikawa, T., Urata, N., Nakamura, J., Suehiro, M., Kawamoto, H., Manabe, N., Kamata, T., & Kawanaka, M. (2020) · Kanzo · doi:10.2957/kanzo.61.438
Ruolo dei farmaci antidiabete nel trattamento della NAFLD
Mantovani, A. (2021) · il Diabete · doi:10.30682/ildia2102b
Ipragliflozin zur Therapie der Fettlebererkrankung bei Typ-2-Diabetes
KAHL, S. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00842-9
Uehira, Y., Ueno, H., Ebihara, E., Uchida, T., Nabekura, H., Sakoda, H., Yonekawa, T., Yamaguchi, H., & Nakazato, M. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13750
Osman, A. A. E.-R. (2022) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2022.223775
Gliflozine bei Typ‑2‑Diabetes und Fettlebererkrankung
KAHL, S. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00922-4
Bệnh gan nhiễm mỡ liên quan chuyển hóa (MAFLD): bệnh hệ thống ngoài gan
Minh, H. Đ. L., & Tuong, T. T. K. (2023) · Pham Ngoc Thach Journal of Medicine and Pharmacy · doi:10.59715/pntjmp.2.1.1
dược, P. Y. (2023) · Pham Ngoc Thach Journal of Medicine and Pharmacy · doi:10.59715/pntjmp.2.1.0
Tontivuthikul, B., Naeowong, W., & Khovidhunkit, W. (2019) · Chula Digiverse · doi:10.58837/chula.the.2019.370
Highlights from the Diabetes UK Professional Conference 2023
Bishop, K. (2023) · Prescriber · doi:10.1002/psb.2096
Einfluss des Optifast-52-Programms auf den Leberfibrosegrad von Patienten mit Adipositas
Gummlich, B. P. M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10189
Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM
Yang, F., & Tan, X. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.121011
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
The liver sinusoid in chronic liver disease: NAFLD and NASH
Kwanten, W. J., & Francque, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00012-7
Lv, X., Mi, D. M., Xin, Y., Dong, W., & Wang, D. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-153404
Deshmukh, N., Kalshetti, M. S., Patil, M., Nandanwar, M., & Sangle, G. V. (2025) · Drug Research · doi:10.1055/a-2557-8927
Bioactive Phytochemical–Based Nanocarriers for Targeting Non‐Alcoholic Fatty Liver Disease (NAFLD)
Kumar, G., Fathima, S., Gurram, P. C., Bala, C., Sindhu, R. K., & Begum, F. (2025) · Wiley eBooks · doi:10.1002/9781394287345.ch16
Yalçın, N., Özkan, A. E., Görgülügil, G. Z., & Koca, N. (2025) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi · doi:10.36516/jocass.1697213
Diabesidad: concepto e implicancias
Lahsen, R. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.08.010
Xie, C., Liu, T., Zhong, Y., Li, Z., Xu, J., Zhao, Z., Wang, X., & Gao, P. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303396313250904204350 · Cited by 1
Hindawy, M. E., Essa, T., Alsaykhan, H., & Gabr, A. M. (2025) · International Journal of Health Sciences · doi:10.25259/ojs_9011
Rivera‐Esteban, J. (2023) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)
Imran, J., Hassan, H., Zannat, T., Ghosh, P., Afsana, F., Azam, M., Amin, M. F., & Pathan, M. F. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_31_25 · Cited by 1
Ozono, Y., Kawakami, H., Hatada, H., Uchiyama, N., Ogawa, S., Uchida, K., Tamura, H., Komaki, Y., Nakamura, K., Iwakiri, H., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04610-1
Yalçın, N., Ertınmaz, A., Görgülügil, G. Z., & Koca, N. (2025) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Soyaltın, U. E., Aliyeva, N. A., Balta, C., Celebi, T., & Şimşir, İ. Y. (2026) · Ege Tıp Dergisi · doi:10.19161/etd.1885126
Samajdar, S. S., Joshi, S., Bhaduri, G., Saboo, B., Roy, K., Mukherjee, S., Bansode, S., & Bandyopadhyay, S. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102898
Helal, E., Shehi, E., Homaid, A. A., Dervishi, M., & Tripathi, D. K. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003264
SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis
Monem, M. S. A., Kamel, A. M. A., Abbassi, M., & Sabry, N. A. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109437
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Empagliflozin’s role in cardiometabolic disease treatment: an Egyptian expert’s view
Khalil, S. H. A., Elmessallamy, F., Elhadidy, K. E., Hefnawy, M. H. M. F. E., Halawa, M. R., Zeitoun, M., Hussein, S., & Elebrashy, I. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02312-y
Metadata
- Authors
- Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K.
- Affiliations
- University of Malaya (MY)
- Corresponding author
- Vethakkan, Shireene Ratna
- Chan, Wah-Kheong
- Venue
- Digestive Diseases and Sciences
- Published
- 2019-01-25
- Volume
- 65
- Issue
- 2
- Pages
- 623-631
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2912523003
- Semantic Scholar
- 70a664f1746784da48173bec3333d56d3992f366
- Cited by
- 191
- References
- 33
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 25 · 2023: 26 · 2022: 34 · 2021: 24 · 2020: 30 · 2019: 12
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Malaya Special Research Fund (Project No.: BK006-2016, BKS067-2017)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, nonalcoholic steatohepatitis, type 2 diabetes, SGLT2 inhibitors, liver histopathology, steatosis, liver fibrosis, ballooning, liver fat fraction, gamma-glutamyl transferase, renal glycosuria, pilot study
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Biopsy, Blood Glucose, Blood Pressure, Cholesterol, Diabetes Mellitus, Type 2, Female, gamma-Glutamyltransferase, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Pilot Projects, Body Mass Index, Treatment Outcome, Waist Circumference, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.